Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder affecting 1% of the population above the age of 65 (Zhang et al., 2000) and is characterized by a selective loss of dopaminergic neurons in the substantia nigra pars compacta. Attempts have been made to understand why the dopaminergic cells are particularly vulnerable, i.e. whether factors intrinsic to these cells contribute to the vulnerability. The presence of dopamine, tyrosine hydroxylase (TH), monoamine oxidase, iron, and/or neuromelanin has been suggested to play a role.
Another molecule endogenously present in dopaminergic neurons that can generate pro-oxidants and induce cell death is tetrahydrobiopterin (BH4). BH4 is an obligatory cofactor for TH in dopamine synthesis (Kaufman, 1993) and is produced selectively in monoaminergic neurons in the brain including the nigral dopaminergic neurons (Hwang et al., 1998, Nagatsu et al., 1995). Interestingly, BH4 exerts toxicity on dopamine-producing cell lines (Anastasiadis et al., 2001, Choi et al., 2000, Enzinger et al., 2002) and primary cultured TH-positive mesencephalic neurons (Lee et al., submitted for publication) but not on non-dopaminergic cells (Choi et al., 2000, Choi et al., 2003a). In vivo, administration of BH4 into animals produces nigrostriatal degeneration, dopamine loss, apoptotic cell death, and motor deficit (Kim et al., 2003). The role of BH4 in dopaminergic cell death is also demonstrated by the report that inhibition of BH4 synthesis can prevent kainate-induced (Foster et al., 2003) and stress-induced (Kim et al., 2005) deaths of nigral dopaminergic neurons. Based on these data, BH4 has been suggested as a candidate endogenous molecule involved in the pathogenesis of PD.
Although the underlying cause of dopaminergic cell death or the mechanism by which these cells degenerate in PD is still not clearly understood, oxidative stress (Beal, 2003, Zhang et al., 2000), mitochondrial dysfunction (Greenamyre et al., 2001, Orth and Schapira, 2002), apoptosis (Anglade et al., 1997, Kingsbury et al., 1998, Mochizuki et al., 1996, Tompkins et al., 1997) and protein misfolding (Dawson and Dawson, 2003, McNaught and Olanow, 2003) are thought to play important roles.
Involvement of mitochondrial dysfunction in PD is based on the findings that a significant decrease in the activity of complex I (NADH:ubiquinone oxidoreductase; EC 1.6.5.3) of the electron transport chain (ETC) is observed in the substantia nigra of postmortem brain (Schapira et al., 1989, Schapira et al., 1990) as well as platelet (Haas et al., 1995, Parker et al., 1989) and skeletal muscle (Mizuno et al., 1998) of PD patients. Reduction in complex IV (cytochrome c oxidase; EC 1.9.3.1) activity has also been observed in PD (Benecke et al., 1993, Schapira, 1994). Reduced activity of ETC can lead to dissipation of mitochondrial membrane potential (ΔΨm) (Ly et al., 2003), which has also been observed in PD (Schapira, 1999). The loss of ΔΨm is related to the release of molecules including cytochrome c and activation of the proapoptotic proteins present close to the outer mitochondrial membrane (Kroemer et al., 1997, Reed, 1997).
Mitochondrial ETC activity is inhibited by reactive oxygen species (ROS) (Brown and Yamamoto, 2003), and extremely sensitive to inhibition by sulfhydryl modifying agents (Gutman et al., 1970a, Gutman et al., 1970b). Exposure of isolated intact mitochondria to dopamine has been demonstrated to lead to impaired oxidative phosphorylation (Berman and Hastings, 1999, Cohen et al., 1997, Khan et al., 2005, Kim et al., 1999), suggesting that the mitochondria can be a target of the species generated by dopamine oxidation. Recent reports suggest the crucial role of quinone products in dopamine-mediated inhibition of mitochondrial function (Khan et al., 2005). Interestingly, our previous study has shown that BH4 facilitates dopamine oxidation leading to formation of reactive quinone products (Choi et al., 2003a), which is important in rendering dopaminergic cells vulnerable.
Based on the findings that (1) the nigral dopaminergic cell death in PD involves mitochondrial dysfunction, oxidative stress and apoptosis; (2) BH4 facilitates generation of oxidative stress and quinone products in dopaminergic cells; and (3) the mitochondria is a target of oxidative damage, it was possible that the BH4-induced dopaminergic cell death involves mitochondrial dysfunction. In the present study we therefore tested whether events related to mitochondrial dysfunction including changes in ETC activity, ΔΨm and cytochrome c release might take place in the BH4-exposed dopaminergic cells.
Section snippets
Materials
RPMI 1640, fetal bovine serum (FBS), horse serum, l-glutamine, trypsin/EDTA, and penicillin–streptomycin were from GibcoBRL (Gaithersburg, MD, USA). BH4, rotenone, N-methyl-4-phenylpyridium (MPP+), antimycin A, coenzyme Q1, cytochrome c, tetramethylphenylene diamine (TMPD), potassium cyanide (KCN), tetramethyl-rhodamine methyl ester (TMRM), and NADH were purchased from Sigma Chemical (St. Louis, MO, USA). Antibody against cytochrome c was obtained from Cell Signaling Technology (Beverly, MA,
BH4 inhibits complexes I and IV activities
To evaluate the effect of BH4 on mitochondrial function in dopaminergic cells, we used CATH.a cells, which have been established in our previous studies as a model to study the BH4-induced dopaminergic cell death (Choi et al., 2000, Choi et al., 2003a, Choi et al., 2003b, Choi et al., 2004, Choi et al., 2005). The cells were treated with BH4 at various concentrations and durations and the enzyme activities of complexes I, II/III, and IV in the mitochondrial fraction were measured by respective
Discussion
We have previously reported that BH4, which is necessary for dopamine synthesis, causes death of dopaminergic cells both in vivo and in vitro by an apoptotic mechanism (Choi et al., 2000, Choi et al., 2003a, Choi et al., 2003b, Kim et al., 2003). As an extension to these studies, the present work demonstrates that BH4 leads to mitochondrial dysfunction, evidenced by the: (1) lowered mitochondrial ETC activity at complexes I and IV; (2) decrease in ΔΨm; and (3) release of mitochondrial
Acknowledgements
HJC and SYL made equal contribution. This work was supported by grants from Korea Research Foundation (2004-005-H00001) and in part by Brain Research Center of the 21st Century Frontier Research Program (M103KV010006 04K2201 00630) funded by the Korea Ministry of Science and Technology, the Korea Health 21 R&D Project (A05-0242-A20718-05N1-00010A) from the Ministry of Health and Welfare, and University of Ulsan Asan Institute for Life Sciences (2003-278) to OH.
References (64)
- et al.
Tetrahydrobiopterin enhances apoptotic PC12 cell death following withdrawal of trophic support
J. Biol. Chem.
(2001) - et al.
Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress
Pharmacol. Ther.
(2003) - et al.
Involvement of apoptosis and calcium mobilization in tetrahydrobiopterin-induced dopaminergic cell death
Exp. Neurol.
(2003) - et al.
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease
Neurochem. Int.
(2005) - et al.
Products of the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase
Arch. Biochem. Biophys.
(1993) - et al.
Reduced pteridine derivatives induce apoptosis in PC12 cells
Neurochem. Int.
(2002) - et al.
Kainic acid lesion-induced nigral neuronal death
J. Chem. Neuroanat.
(2003) - et al.
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
Eur. J. Pharmacol.
(1995) - et al.
Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XVII. Reaction sites of piericidin A and rotenone
J. Biol. Chem.
(1970) - et al.
Characterization of the mitochondrial respiratory pathways in Candida albicans
Biochim. Biophys. Acta
(2002)
Dopamine induced protein damage in mitochondrial–synaptosomal fraction of rat brain
Brain Res.
Degeneration of the nigrostriatal pathway and induction of motor deficit by tetrahydrobiopterin: an in vivo model relevant to Parkinson's disease
Neurobiol. Dis.
The autoxidation of tetrahydrobiopterin revisited. Proof of superoxide formation from reaction of tetrahydrobiopterin with molecular oxygen
J. Biol. Chem.
Mitochondrial control of apoptosis
Immunol. Today
Histochemical detection of apoptosis in Parkinson's disease
J. Neurol. Sci.
Mitochondrial involvement in Parkinson's disease
Neurochem. Int.
Involvement of oxidative stress on the impairment of energy metabolism induced by a beta peptides on PC12 cells: protection by antioxidants
Neurobiol. Dis.
Cytochrome c: can’t live with it — can’t live without it
Cell
The role of mitochondrial oxidative stress in aging
Free Radical Biol. Med.
Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
Biochim. Biophys. Acta
Mitochondrial complex I deficiency in Parkinson's disease
Lancet
High-throughput measurement of mitochondrial membrane potential in a neural cell line using a fluorescence plate reader
Biochem. Biophys. Res. Commun.
Oxidative stress and genetics in the pathogenesis of Parkinson's disease
Neurobiol. Dis.
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
Histol. Histopathol.
Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
Neurotox. Res.
Mitochondria, oxidative damage, and inflammation in Parkinson's disease
Ann. N.Y. Acad. Sci.
Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes
Brain
Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease
J. Neurochem.
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Nat. Neurosci.
Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress
Mol. Pharmacol.
Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease
J. Neurochem.
JNK activation by tetrahydrobiopterin: implication for Parkinson's disease
J. Neurosci. Res.
Cited by (47)
Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases
2022, European Journal of PharmacologyMitochondrial quality control: Epigenetic signatures and therapeutic strategies
2021, Neurochemistry InternationalPossible involvement of tetrahydrobiopterin in the disturbance of redox homeostasis in sepsis – Induced brain dysfunction
2018, Brain ResearchCitation Excerpt :Interestingly, we could not find neurotoxic effects of high level of BH4 in non-septic rats, in spite that previous studies concluded that non-physiological BH4 concentrations could be cytotoxic. They reported that neuronal cells undergo apoptosis and oxidative stress from high BH4 concentration (Yu et al., 2014; Choi et al., 2000; Choi et al., 2006; Choi et al., 2004). Furthermore, Choi et al., 2003 speculated that chronic overproduction and release of BH4 in vivo could lead to enhanced oxidative stress and apoptotic death of the dopaminergic neurons.
Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease
2017, Neurobiology of AgingCitation Excerpt :It is likely that in the absence of BH4 reductase (AR), or when there is reduced level of TH, over-activation of their respective alternate BH4, and dopamine synthetic pathways may contribute to their increases. Since both BH4 and dopamine are unstable and highly reactive in the cell, they can readily undergo autoxidation or enzymatic metabolism to generate toxic ROS and cause mitochondrial dysfunction (Choi et al., 2006). Increasing evidence implicates mitochondrial dysfunction resulting from molecular defects in OXPHOS.
mTOR, Autophagy, Aminoacidopathies, and Human Genetic Disorders
2016, Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies